# Amlogenyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amlogenyx

- Industry: Biotechnology
- Headquarters: Novato, US
- Total disclosed funding: $14M
- Latest round: Seed (Jul 26, 2024)
- Investors on record: 2

## About

Founded in 2023 and based in California, US, Amlogenyx Inc. operates as a novel gene therapeutics company. In July 2024, Amlogenyx Inc. raised USD 14 million in seed funding led by GordonMD Global Investments and Ultragenyx Pharmaceutical Inc. The seed funding values Amlogenyx Inc. at USD 48.49 million post-money.

Amlogenyx develops novel gene therapies for Alzheimer’s disease and other amyloid diseases. The company’s lead product candidate is a protease (an enzyme that breaks down proteins) developed in collaboration with St. Jude Children's Research Hospital. The enzyme breaks down and degrades Aß42, a protein widely believed to be a key factor in the development of Alzheimer's disease.

The company plans to utilize the funding raised in July 2024 to support the development of amyloid disease treatment.

## Funding rounds

- Seed, Jul 26, 2024, $14M — Ultragenyx Pharmaceutical Inc., GordonMD Global Investments

## Investors

- Ultragenyx Pharmaceutical Inc. — Seed
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Seed